|Mr. Armando Anido M.B.A., MBA||Chairman & CEO||901.21k||N/A||1958|
|Ms. Terri B. Sebree||Pres||681.77k||N/A||1958|
|Mr. James E. Fickenscher||CFO & VP of Corp. Devel.||260.09k||N/A||1964|
|Mr. William C. Roberts||VP of Investor Relations & Corp. Communications||N/A||N/A||1969|
|Ms. Suzanne M. Hanlon||Sec., VP of HR & Gen. Counsel||N/A||N/A||1957|
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Zynerba Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2018 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 6; Compensation: 9.